SD - Solventum Corp (0001964738) (Filer)

8-K - Solventum Corp (0001964738) (Filer)

8-K - Solventum Corp (0001964738) (Filer)

10-Q - Solventum Corp (0001964738) (Filer)

8-K - Solventum Corp (0001964738) (Filer)

DEFA14A - Solventum Corp (0001964738) (Filer)

DEF 14A - Solventum Corp (0001964738) (Filer)

SCHEDULE 13G/A - Solventum Corp (0001964738) (Subject)

8-K - Solventum Corp (0001964738) (Filer)

10-K - Solventum Corp (0001964738) (Filer)

EAGAN, Minn., May 27, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the Jefferies Healthcare Conference on Wednesday, Jun. 3, 2026, beginning at approximately 9:55 a.m. EDT in New York, NY. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challenges, we pion

ST. PAUL, Minn., May 7, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a fireside chat at the BofA Securities Health Care Conference on Wednesday, May 13, 2026, beginning at approximately 10:00 a.m. PDT in Las Vegas, NV. A live and archived replay of the fireside chat will be available on the company's website at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest challeng

Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating

Solventum's Spin-Out from 3M has Maximized Executive Compensation, Not Shareholder Value Outlines Three Initiatives to Improve Performance and Drive Value Creation at Solventum NEW YORK, April 30, 2026 (GLOBE NEWSWIRE) -- Trian Fund Management, L.P. ("Trian"), which beneficially owns nearly 5% of Solventum Corporation's common stock (NYSE:SOLV) ("Solventum" or the "Company") and is one of the Company's largest active shareholders, today published an open letter to the Solventum Board of Directors (the "Board") and an accompanying slide deck arguing that the Company continues to be significantly under-managed following its spin-out from 3M – and outlining three immediately actionable

ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Tuesday, May 5, 2026Time:3:30 p.m. CDT / 4:30 p.m. EDTLocation:https://investors.solventum.com U.S. dial-in+1 (800) 715-9871International dial-in: +1 (646) 307-1963Conference ID:63

ST. PAUL, Minn., March 11, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that management will participate in a virtual fireside chat at the KeyBanc Healthcare Forum on Wednesday, Mar. 18, 2026, beginning at approximately 10:30 a.m. EDT. More information about this event, including access to the live webcast and the webcast replay, will be available at investors.solventum.com.About SolventumAt Solventum, we enable better, smarter, safer healthcare to improve lives. As a new company with a long legacy of creating breakthrough solutions for our customers' toughest chal

The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So

ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Feb. 26, 2026 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 Internation

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac

The Middleby Corporation (NASDAQ:MIDD), a global leader in the foodservice industry, today announced the appointment of Glenn Eisenberg to its Board of Directors, effective March 1. With the addition of Mr. Eisenberg, the Middleby Board expands to twelve members. "We are pleased to welcome Glenn Eisenberg to the Middleby Board. His deep experience will be an immediate asset as we execute our strategic transformation," said Tim FitzGerald, Middleby CEO. "Glenn has a proven 20-year track record of success as a public company CFO and senior operating executive across complex global manufacturing businesses. His expertise in financial discipline, industrial manufacturing, capital allocation,

ST. PAUL, Minn., Oct. 21, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today the appointment of Heather Knight as Chief Commercial Officer, effective November 10, 2025. In this newly created role, Ms. Knight will oversee global commercial and R&D operations across Solventum's MedSurg, Dental Solutions and Health Information Systems segments, and will report directly to CEO Bryan Hanson. Ms. Knight brings over 30 years of leadership experience in the MedTech industry. Most recently, she served as Chief Operating Officer at Baxter International, where she led global sale

BOSTON, Feb. 11, 2025 (GLOBE NEWSWIRE) -- Ampersand Biomedicines, a multi-product platform company developing smarter medicines that act specifically at the site of disease and nowhere else, today announced the appointment of Elizabeth Mily to its Board of Directors as Independent Director. A highly respected healthcare and financial industry veteran with more than 30 years of experience, Mily brings extensive expertise in corporate strategy, business development and investment leadership to Ampersand as it advances its Address, Navigate, Determine (AND)™ Platform to develop programmed biologics. "We are thrilled to welcome Elizabeth to Ampersand's Board as we leverage our AND Platform to

Former Bristol Myers Squibb, Goldman Sachs, and Barclays executive brings deep expertise in corporate strategy, partnership development, public and private financial markets, and management as the organization evolves its leadership and investment strategy Appointment signals plans to capitalize on previous success and maximize impact by expanding equity investments and partnerships with venture capital, large biopharma, and key foundations with a proven team leader and dealmaker BOSTON, Jan. 8, 2025 /PRNewswire/ -- The T1D Fund, an impact investment fund with a focus on accelerating life-changing solutions to treat, prevent, and cure type 1 diabetes (T1D), today announced it appointed Eliza

ST. PAUL, Minn., Oct. 10, 2024 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today that Dr. Ryan Egeland, MD, has been named chief medical officer. Dr. Egeland is responsible for leading Solventum's Global Medical and Clinical Affairs team, amplifying the voice of clinicians and patients. In this role, he will focus on fostering industry collaboration and identifying innovation and market expansion opportunities at the intersection of scientific rigor, clinical need, and commercial practicality. Dr. Egeland will report to Chris Barry, executive vice president and group presi

Reported sales decreased (3.0)%; organic sales increased 2.1%Affirms full-year 2026 organic sales growth and free cash flow guidance; estimates adjusted EPS will be toward the high end of existing rangeEAGAN, Minn., May 5, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2026. First Quarter 2026 HighlightsSales of $2.0 billion decreased (3.0)% on a reported basis; an increase of 2.1% on an organic basisGAAP diluted earnings per share of $0.07; adjusted diluted earnings per share of $1.48, a 10.6% increaseOperating

ST. PAUL, Minn., April 14, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its first quarter fiscal 2026 financial results on Tuesday, May 5, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Tuesday, May 5, 2026Time:3:30 p.m. CDT / 4:30 p.m. EDTLocation:https://investors.solventum.com U.S. dial-in+1 (800) 715-9871International dial-in: +1 (646) 307-1963Conference ID:63

Reported sales decreased 3.7%; organic sales increased 3.5%Introduces full-year 2026 organic sales growth, adjusted EPS and free cash flow guidanceST. PAUL, Minn., Feb. 26, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the fourth quarter and year ended December 31, 2025. Fourth Quarter 2025 HighlightsSales of $2 billion decreased 3.7% on a reported basis; an increase of 3.5% on an organic basisGAAP diluted earnings per share of $0.36; adjusted diluted earnings per share of $1.57Operating cash flow of $96 million; free cash flow of $33 million"So

ST. PAUL, Minn., Feb. 3, 2026 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its fourth quarter fiscal 2025 financial results on Thursday, Feb. 26, 2026, after the U.S. financial markets close. Following the release, Solventum management will host a webcast to discuss the results and fiscal year 2026 outlook. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Feb. 26, 2026 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 Internation

Expands MedSurg portfolio into the fast-growing synthetic tissue matrices technology space in acute care settings in the U.S.Accelerates Solventum's business transformation through the acquisition of a strategically aligned asset in a technology adjacencyST. PAUL, Minn., Dec. 23, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) announced today it has completed the acquisition of Acera Surgical (Acera), a privately held bioscience company focused on developing and commercializing fully engineered materials for regenerative wound care. "Announcing and completing our first strategic ac

Reported sales increased 0.7%; organic sales increased 2.7%Expects full year organic sales growth to be at the high end of +2.0% to +3.0% rangeIncreases full year adjusted earnings per share outlook to $5.98 to $6.08Announces 4-year 'Transform for the Future' initiativeST. PAUL, Minn., Nov. 6, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the third quarter ended September 30, 2025. Third Quarter 2025 Highlights Sales increased 0.7% to $2.1 billion; up 2.7% on an organic basisGAAP diluted earnings per share of $7.22; adjusted diluted earnings p

ST. PAUL, Minn., Oct. 16, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its third quarter fiscal 2025 financial results on Thursday, Nov. 6, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Nov. 6, 2025 Time: 3:30 p.m. CST / 4:30 p.m. EST Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (6

Reported sales increased 3.9%; organic sales increased 2.8%Increases full year organic sales growth outlook to +2.0% to +3.0%Increases full year earnings per share outlook to $5.80 to $5.95ST. PAUL, Minn., Aug. 7, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the second quarter ended June 30, 2025. Second Quarter 2025 Highlights Sales increased 3.9% to $2.2 billion; up 2.8% on an organic basisGAAP diluted earnings per share of $0.51; adjusted diluted earnings per share of $1.69Operating cash flow of $169 million; free cash flow of $59 million"

ST. PAUL, Minn., July 17, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) will release its second quarter fiscal 2025 financial results on Thursday, Aug. 7, 2025, after the U.S. financial markets close. After the release, Solventum management will host a webcast to discuss the results and its business. Other forward-looking and material information may also be discussed during the webcast. Earnings webcast details: Date: Thursday, Aug. 7, 2025 Time: 3:30 p.m. CDT / 4:30 p.m. EDT Location: https://investors.solventum.com U.S. dial-in +1 (800) 715-9871 International dial-in: +1 (

Reported sales increased 2.6%; organic sales increased 4.3%Increases full year organic sales growth outlook by 50 bps to +1.5% to +2.5%ST. PAUL, Minn., May 8, 2025 /PRNewswire/ -- Solventum (NYSE:SOLV) today reported financial results for the first quarter ended March 31, 2025. First Quarter 2025 Highlights Sales increased 2.6% to $2.1 billion; up 4.3% on an organic basisGAAP diluted earnings per share of $0.78; adjusted diluted earnings per share of $1.34Operating cash flow of $29 million; free cash flow of $(80) million"Our first quarter fiscal year 2025 results reflect soli

SC 13G/A - Solventum Corp (0001964738) (Subject)

SC 13G/A - Solventum Corp (0001964738) (Subject)